When your doctor talks about a new medicine for your arthritis, diabetes, or cancer, you might hear the word biosimilar. It sounds technical, maybe even confusing. But here’s the truth: biosimilars aren’t some experimental trick. They’re real, tested, and approved medicines designed to work just like the original biologic drugs you’ve been prescribed - often at a lower cost.
What’s the difference between a biosimilar and a generic drug?
Most people know generics. They’re the cheaper versions of pills like ibuprofen or metformin. Generics are exact chemical copies. If you break open a generic pill, you’ll find the same molecules as the brand-name version. Biosimilars are different. They’re not copies in the same way. Why? Because biologic drugs aren’t made in a lab with chemicals. They’re made using living cells - like yeast, bacteria, or animal cells - that are genetically programmed to produce complex proteins. These proteins can be thousands of times bigger than a regular drug molecule. Think of it like building a Lego castle vs. building a single Lego brick. The castle has many pieces, shapes, and connections that are hard to perfectly replicate. So a biosimilar isn’t identical to the original biologic. But it’s as close as science can get. The FDA requires hundreds of tests to prove it behaves the same way in the body. The same immune response. The same safety profile. The same effectiveness. If there’s any difference, it has to be so tiny that it doesn’t affect how well the medicine works or whether it causes side effects.How do we know biosimilars are safe?
You might worry: “If it’s not the same, could it be less safe?” That’s a fair question. But here’s what the data shows. Before a biosimilar gets approved, it goes through more testing than most new drugs. Scientists compare its molecular structure to the original biologic down to the smallest detail. They test it in animals. Then they run clinical trials with hundreds of patients - sometimes over a thousand - comparing side effects, how long the drug lasts in the body, and how well it controls the disease. Take Renflexis, a biosimilar for rheumatoid arthritis. Before approval, it was tested in 541 patients. The results? No meaningful difference in safety or effectiveness compared to the original drug, infliximab. In Europe, biosimilars have been used for over 15 years. Millions of patients have taken them. No new safety risks have shown up. The FDA and other global health agencies agree: approved biosimilars are just as safe as the originals.What conditions are treated with biosimilars?
Biosimilars aren’t for every illness. They’re used for complex, chronic conditions that need biologic drugs to treat them. That includes:- Rheumatoid arthritis, psoriasis, and Crohn’s disease (using drugs like adalimumab and infliximab)
- Type 1 and type 2 diabetes (insulin glargine biosimilars)
- Certain cancers, like breast cancer and colon cancer (trastuzumab, bevacizumab)
- Chronic kidney disease (epoetin alfa for anemia)
- Macular degeneration (ranibizumab for vision loss)
Will my insurance make me switch to a biosimilar?
Maybe. Many insurance plans now prefer biosimilars because they’re cheaper. Some plans will only pay for the biosimilar version unless your doctor says the original is medically necessary. That doesn’t mean you’ll be forced to switch. Your doctor still decides what’s best for you. If you’ve been stable on your current biologic for years, your provider may keep you on it. But if you’re starting treatment, or if cost is a barrier, a biosimilar is a smart, safe option. If your pharmacy gives you a biosimilar instead of the brand name, check the name on the box. Biosimilars have the same generic name as the original - but with a four-letter ending. For example:- Original: adalimumab
- Biosimilar: adalimumab-atto
Can I switch from a biologic to a biosimilar?
Yes. Studies show switching is safe. The Arthritis Foundation, the American Cancer Society, and the FDA all say there’s no increased risk when moving from a brand-name biologic to a biosimilar. One big study followed over 1,000 patients with inflammatory bowel disease who switched from the original drug to a biosimilar. After a year, their symptoms stayed under control. No new side effects showed up. Another study looked at patients with rheumatoid arthritis - same result. If you’re nervous about switching, talk to your doctor. Ask: “Has this biosimilar been tested in people like me?” “What’s the evidence?” Most doctors are confident in biosimilars because the data is strong.
What about interchangeable biosimilars?
There’s a special category called “interchangeable” biosimilars. These are biosimilars that the FDA says can be swapped for the original drug even without the doctor’s approval - just like a generic pill. The first one approved was Semglee, an insulin glargine biosimilar for diabetes. In 2023, more interchangeable biosimilars hit the market, especially for insulin and arthritis drugs. This doesn’t mean you’ll automatically get switched. But it does mean your pharmacist can swap the brand for the biosimilar without calling your doctor - unless your state or plan says otherwise.Will biosimilars keep getting cheaper?
Yes. As more companies enter the market, prices will drop. Between 2017 and 2026, biosimilars are expected to save the U.S. healthcare system over $54 billion. Right now, only about 10% of biologic prescriptions in the U.S. are for biosimilars. In Europe, it’s over 25%. That gap is closing fast. More biosimilars are in the pipeline - for cancer, autoimmune diseases, and even rare conditions. The FDA is working to speed up approvals and make sure doctors and patients have clear information. That means more choices, lower costs, and better access - without sacrificing safety.What should you do as a patient?
If your doctor suggests a biosimilar:- Ask: “Is this approved by the FDA?”
- Ask: “Has it been used in other patients with my condition?”
- Ask: “What’s the difference in cost?”
Are biosimilars the same as generics?
No. Generics are exact chemical copies of small-molecule drugs like aspirin or metformin. Biosimilars are highly similar versions of complex biologic drugs made from living cells. They can’t be exact copies because the molecules are too large and complex. But they’re proven to work the same way in the body.
Are biosimilars safe?
Yes. Every FDA-approved biosimilar has gone through extensive testing - including analytical studies, animal tests, and clinical trials with hundreds or thousands of patients. Studies in Europe and the U.S. show no new safety risks compared to the original biologic. The FDA requires that biosimilars have no clinically meaningful differences in safety or effectiveness.
Can I switch from my current biologic to a biosimilar?
Yes. Multiple studies have shown that switching from a brand-name biologic to a biosimilar is safe and doesn’t reduce effectiveness. Patients with arthritis, Crohn’s disease, and other conditions have switched without increased side effects or loss of symptom control. Always talk to your doctor before switching, but there’s no medical reason to avoid it.
Why do biosimilars have different names?
Biosimilars have the same generic name as the original biologic, but with a four-letter suffix added - like infliximab-dyyb. This helps doctors, pharmacists, and patients track which product was given if there’s ever a safety issue. It’s not meant to confuse you - it’s for safety.
Will my insurance cover a biosimilar?
Most plans now prefer biosimilars because they’re cheaper - often 15% to 30% less than the original. Some plans require you to try a biosimilar first before covering the brand-name drug. But your doctor can still prescribe the original if there’s a medical reason. Always check with your insurance or pharmacist about what’s covered.
Are biosimilars new and untested?
No. The first biosimilar was approved in the U.S. in 2015. Since then, over 40 have been approved, and millions of patients worldwide have used them safely for over 15 years - especially in Europe. They’re not experimental. They’re backed by decades of research and real-world use.
Write a comment